Efficacy of switching to telbivudine in chronic hepatitis B patients treated previously with lamivudine

Liver International

Volumn 31, Issue 5, 2011, Pages 667-675

  Safadi, Rifaat ^a,b   Xie, Qing ^c   Chen, Yagang ^d   Yin, You Kuan ^e   Wei, Lai ^f   Hwang, Seong Gyu ^g   Zuckerman, Eli ^h   Jia, Ji Dong ⁱ   Lopez, Patricia ^j  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b Israel   (Israel)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d ZHEJIANG UNIVERSITY   (China)

^e FUDAN UNIVERSITY   (China)

^f PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^g Cha University   (South Korea)

^h CARMEL MEDICAL CENTER   (Israel)

ⁱ CAPITAL MEDICAL UNIVERSITY   (China)

^j NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

Chronic hepatitis B; HBV DNA; Lamivudine; Nucleoside analogue; Telbivudine switch

Indexed keywords

LAMIVUDINE; TELBIVUDINE; VIRUS DNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEART INFARCTION; HEMORRHOID; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUTATION; MYALGIA; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIREMIA; VIRUS REPLICATION;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; DNA, VIRAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG SUBSTITUTION; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; NUCLEOSIDES; PYRIMIDINONES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 79953307451     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02360.x     Document Type: Article

References (17)

1. Gaeta GB, Stornaiuolo G. Therapy of chronic hepatitis B: focus on telbivudine. Dig Liver Dis 2007; 39: S372-8.
2. Iloeje UH, Yang HI, Jen CL, et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol 2007; 5: 921-31.
3. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
4. Chen G, Lin W, Shen F, et al. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006; 101: 1797-803.
5. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
6. Ferir G, Kaptein S, Neyts J, De Clercq E. Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future. Rev Med Virol 2008; 18: 19-34.
7. Lampertico P, Vigano M, Colombo M. Management of lamivudine resistance: an overview. Hepatitis B Annu 2008; 5: 66-80.
8. Liaw YF, Gane E, Leung N, et al. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-95.
9. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 528-36.
10. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
11. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
12. Libbrecht E, Doutreloigne J, Van De Velde H, et al. Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay. J Clin Microbiol 2007; 45: 3935-41.
13. Kurashige N, Hiramatsu N, Ohkawa K, et al. Initial viral response is the most powerful predictor of the emergence of YMDD mutant virus in chronic hepatitis B patients treated with lamivudine. Hepatol Res 2008; 38: 450-6.
14. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia hepatitis lamivudine study group. Gastroenterology 2000; 119: 172-80.
15. Leung NWY, Lai CL, Chang TT, et al. Three year lamivudine therapy in chronic HBV. J Hepatology 1999; 30: 59, Abstract (GS5/25).
16. Leung N. Treatment of chronic hepatitis B: case selection and duration of therapy. J Gastroenterol Hepatol 2002; 17: 409-14.
17. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-88.